PURPOSE: To report outcomes, failures, and toxicities in patients treated with intensity-modulated radiotherapy (IMRT) for squamous cell carcinoma of the oropharynx. METHODS AND MATERIALS: Between Aug 2001 and Oct 2007, 107 patients were treated with IMRT with curative intent at Stanford University. Twenty-two patients were treated postoperatively, and 85 were treated definitively. Concurrent platinum-based chemotherapy was administered to 86 patients (80%) and cetuximab to 8 patients (7%). The prescribed dose was 66 Gy at 2.2 Gy/fraction for definitively treated cases and 60 Gy at 2 Gy/fraction for postoperative cases. Median follow-up was 29 months among surviving patients (range, 4-105 months). RESULTS: Eight patients had persistent disease or local-regional failure at a median of 6.5 months (range, 0-9.9 months). Six local failures occurred entirely within the high-risk clinical target volume (CTV) (one with simultaneous distant metastasis). One patient relapsed within the high- and intermediate-risk CTV. One patient had a recurrence at the junction between the IMRT and low-neck fields. Seven patients developed distant metastasis as the first site of failure. The 3-year local-regional control (LRC), freedom from distant metastasis, overall survival, and disease-free survival rates were 92%, 92%, 83%, and 81%, respectively. T stage (T4 vs. T1-T3) was predictive of poorer LRC (p = 0.001), overall survival (p = 0.001), and disease-free survival (p < 0.001) rates. Acute toxicity consisted of 58% grade 3 mucosal and 5% grade 3 skin reactions. Six patients (6%) developed grade >or=3 late complications. CONCLUSIONS: IMRT provides excellent LRC for oropharyngeal squamous cell carcinoma. Distant metastases are a major failure pattern. No marginal failures were observed.
PURPOSE: To report outcomes, failures, and toxicities in patients treated with intensity-modulated radiotherapy (IMRT) for squamous cell carcinoma of the oropharynx. METHODS AND MATERIALS: Between Aug 2001 and Oct 2007, 107 patients were treated with IMRT with curative intent at Stanford University. Twenty-two patients were treated postoperatively, and 85 were treated definitively. Concurrent platinum-based chemotherapy was administered to 86 patients (80%) and cetuximab to 8 patients (7%). The prescribed dose was 66 Gy at 2.2 Gy/fraction for definitively treated cases and 60 Gy at 2 Gy/fraction for postoperative cases. Median follow-up was 29 months among surviving patients (range, 4-105 months). RESULTS: Eight patients had persistent disease or local-regional failure at a median of 6.5 months (range, 0-9.9 months). Six local failures occurred entirely within the high-risk clinical target volume (CTV) (one with simultaneous distant metastasis). One patient relapsed within the high- and intermediate-risk CTV. One patient had a recurrence at the junction between the IMRT and low-neck fields. Seven patients developed distant metastasis as the first site of failure. The 3-year local-regional control (LRC), freedom from distant metastasis, overall survival, and disease-free survival rates were 92%, 92%, 83%, and 81%, respectively. T stage (T4 vs. T1-T3) was predictive of poorer LRC (p = 0.001), overall survival (p = 0.001), and disease-free survival (p < 0.001) rates. Acute toxicity consisted of 58% grade 3 mucosal and 5% grade 3 skin reactions. Six patients (6%) developed grade >or=3 late complications. CONCLUSIONS: IMRT provides excellent LRC for oropharyngeal squamous cell carcinoma. Distant metastases are a major failure pattern. No marginal failures were observed.
Authors: Chad Tang; James D Murphy; Brian Khong; Trang H La; Christina Kong; Nancy J Fischbein; A Dimitrios Colevas; Andrei H Iagaru; Edward E Graves; Billy W Loo; Quynh-Thu Le Journal: Int J Radiat Oncol Biol Phys Date: 2012-01-21 Impact factor: 7.038
Authors: Kee H Wong; Rafal Panek; Shreerang A Bhide; Christopher M Nutting; Kevin J Harrington; Katie L Newbold Journal: Br J Radiol Date: 2017-03 Impact factor: 3.039
Authors: Glenn J Hanna; Alec Kacew; Nicole G Chau; Priyanka Shivdasani; Jochen H Lorch; Ravindra Uppaluri; Robert I Haddad; Laura E MacConaill Journal: JCI Insight Date: 2018-09-06
Authors: Robert L Foote; Yolanda I Garces; Michelle A Neben Wittich; Daniel J Ma; Sean S Park; Julian R Molina; Scott H Okuno; Katharine A Price; Steven E Schild; Samir H Patel Journal: Mayo Clin Proc Date: 2012-11 Impact factor: 7.616
Authors: Matthew E Spector; Steven B Chinn; Emily Bellile; K Kelly Gallagher; Mohannad Ibrahim; Jeffrey Vainshtein; Eric J Chanowski; Heather M Walline; Jeffrey S Moyer; Mark E Prince; Gregory T Wolf; Carol R Bradford; Jonathan B McHugh; Thomas Carey; Francis P Worden; Avraham Eisbruch; Douglas B Chepeha Journal: Head Neck Date: 2015-06-30 Impact factor: 3.147
Authors: Matthew E Spector; K Kelly Gallagher; Emily Light; Mohannad Ibrahim; Eric J Chanowski; Jeffrey S Moyer; Mark E Prince; Gregory T Wolf; Carol R Bradford; Kitrina Cordell; Jonathan B McHugh; Thomas Carey; Francis P Worden; Avraham Eisbruch; Douglas B Chepeha Journal: Head Neck Date: 2012-01-13 Impact factor: 3.147
Authors: M de Ridder; Z A R Gouw; J J Sonke; A Navran; B Jasperse; J Heukelom; M E T Tesselaar; W M C Klop; M W M van den Brekel; Abrahim Al-Mamgani Journal: Eur Arch Otorhinolaryngol Date: 2016-12-09 Impact factor: 2.503